posted
Rheologics Blood Viscosity Testing Update Thursday January 25, 9:56 pm ET
EXTON, PA--(MARKET WIRE)--Jan 25, 2007 -- Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc. (Other OTC:RTGI.PK - News) ("Rheologics"), the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce that its Laboratory Services unit has received an encouraging number of requests for its Whole Blood Viscosity (WBV) testing program. The Company believes that in addition to gathering important clinical data, the initial response indicates a strong demand for the service. ADVERTISEMENT
For physicians, general practitioners, and internists, knowing the viscosity of their patients' blood provides a critical tool in evaluating the efficiency and health of a cardiovascular system. The role that blood viscosity plays in cardiovascular health is substantial. Since the cardiovascular system is a closed system, the viscosity or thickness of what the heart is pumping directly affects the heart's efficiency and the damage done to the arteries by blood flow.
As part of the program, patients' blood specimens are drawn at their physicians' offices into standard vacutainers and shipped overnight in a cold pack to Rheologics' laboratory facility in Exton, Pennsylvania. Rheologics provides physicians with the specimen collection kits used for convenient packing and shipping. Test results include a graph of the WBV Profile of the patient's blood against a benchmark as well as an interpretive guide. The results are typically provided within 24 hours. For more information about the program, doctors can contact the Company at www.rheologics.com
Rheologics believes that its whole blood viscosity test will be comparable to cholesterol testing in terms of its commercial reach and clinical impact. The U.S. market for the LDL cholesterol testing is estimated at 65 million tests per year, while the U.S. market for HDL cholesterol tests is estimated at 100 million tests per year.
Cardiovascular disease is one of the leading causes of death in the United States, affecting more than 62 million Americans and claiming the lives of nearly one million people in the U.S. per year. Globally, over 17 million people die from vascular diseases, mostly heart attacks and strokes.
The Rheolog® is an FDA IDE-exempt device approved for research and for providing additional information in the interpretation of a disease condition and therefore is not covered by insurance plans.
About Rheologics Technologies, Inc.
Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventative diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.
Contact: Contact: Contact Rheologics: Daniel Cho 800-969-2585 Email Contact
posted
Looking good today, light volume but L2 lining up like it's ready.
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
posted
Study: Blood Viscosity Shown to Be Elevated in Scleroderma Patients Wednesday January 31, 8:25 am ET
EXTON, PA--(MARKET WIRE)--Jan 31, 2007 -- Rheologics Technologies, Inc. (Other OTC:RTGI.PK - News) ("Rheologics," the "Company"), the leader in the study of blood viscosity and its relationship to vascular diseases, announced today the results of a study performed at the University of Chicago using the Rheolog®, the Company's proprietary blood viscometer. The research demonstrated significantly higher blood viscosity in scleroderma patients over health controls and, among scleroderma patients, higher blood viscosity in patients having active digital (finger) ulcers over those scleroderma patients that did not.
Scleroderma, also called systemic sclerosis, is an autoimmune disease where the body's immune system attacks its own tissues, resulting in the formation of scar tissue and a hardening of the skin and internal organs. Women are more commonly affected than men, and patients are generally between the ages of 30 and 50. Approximately 300,000 people in the U.S. are affected with scleroderma.
Over 90 percent of scleroderma patients develop what is called Raynaud's phenomenon characterized by blue and red discoloration of the hands and often leading to painful digital (finger) ulcers. Although Raynaud's phenomenon is known to be closely related to the regulation of blood flow in the fingers, it is not yet understood why only some patients with scleroderma develop the ulcers. Furthermore, the root causes of scleroderma and also of Raynaud's phenomenon are not well understood.
The University of Chicago study included a healthy control group matched by age, gender, race and body-mass index and 33 randomly selected scleroderma patients. Among the scleroderma patients were those with active digital (finger) ulcers and those without. Using the Rheolog®, it was demonstrated that scleroderma patients with active digital ulcers had significantly higher blood viscosity than those without the ulcers. The difference was more pronounced in the low shear rate range of blood flow (i.e., under conditions where blood is moving slowly as in the microvessels). Overall, scleroderma patients had significantly higher blood viscosity than healthy controls.
Kenneth Kensey, MD, founder and Chief Scientific Officer of Rheologics, said, "The importance of blood viscosity is easily accepted by rheumatologists because they already use a parameter called erythrocyte sedimentation rate ('ESR' or 'sed' rate), which is a very primitive analog of the whole blood viscosity profiles generated by our Rheolog® device. This Chicago study demonstrates the importance of measuring blood viscosity in patients with scleroderma as a potential predictor of the onset of Raynaud's.
"Interestingly, we see a higher risk of heart attack and stroke in scleroderma patients, but what I believe is more important is that poor blood flow is being recognized as a common link driving a number of different diseases. Whether we are talking about the amputated fingers of a scleroderma patient, the amputation of the leg of a diabetic with peripheral vascular disease, glaucoma, macular degeneration, Alzheimer's or vascular dementia, or more generally, heart attacks and strokes, we need to understand thoroughly how the flow of blood impacts the progression of disease. While these diseases and many others are still incurable, understanding blood flow can help us greatly improve the quality of care we provide and the quality of life for our patients. Whole blood viscosity is the parameter that quantifies the blood's ability to flow and has the potential to unleash a wave of medical advances." Dr. Kensey is a cardiologist and the Chairman of Rheologics. As CEO of Kensey-Nash Corporation prior to founding Rheologics, he was responsible for the creation of interventional devices used today in hospitals around the world.
The Rheolog® is an IDE-exempt device approved for research and for providing additional information in the interpretation of disease.
About Rheologics Technologies, Inc.
Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.
Contact: Contact Rheologics: Daniel Cho 800-969-2585 Email Contact
-------------------------------------------------------------------------------- Source: Rheologics Technologies, Inc.
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
posted
.04's printed nicely today. Looking for additional strengthening in the market.
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
posted
.04's again today. 30+% every other day, who can complain?
-------------------- FurrySound -DD-GLTA-Unless I've quoted a source, I know not what I speak of. YahooIM=FurrySound Posts: 2170 | From: Pennsylvania, USA | Registered: Mar 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
